This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
serious infections reactivation of hepatitis B reactivation of tuberculosis lethal hepatosplenic T-cell lymphoma (generally only when combined with 6-mercaptopurine) drug-induced lupus demyelinating central nervous system disorders psoriasis and psoriasiform skin lesions new-onset vitiligo Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab. The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully. The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents. Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with methotrexate (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease. The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks.
by Kimura). In 1981, Joseph Felsenstein proposed a four-parameter model (F81) in which the substitution rate corresponds to the equilibrium frequency of the target nucleotide. Hasegawa, Kishino, and Yano unified the two last models to a five-parameter model (HKY). After these pioneering efforts, many additional sub-models of the GTR model were introduced into the literature (and common use) in the 1990s. Other models that move beyond the GTR model in specific ways were also developed and refined by several researchers. Almost all DNA substitution models are mechanistic models (as described above). The small number of parameters that one needs to estimate for these models makes it feasible to estimate those parameters from the data. It is also necessary because the patterns of DNA sequence evolution often differ among organisms and among genes within organisms. The later may reflect optimization by the action of selection for specific purposes (e.g. fast expression or messenger RNA stability) or it might reflect neutral variation in the patterns of substitution. Thus, depending on the organism and the type of gene, it is likely necessary to adjust the model to these circumstances.
==== Gel electrophoresis under non-denaturing conditions ==== Non-denaturing gel electrophoresis allows proteins to maintain their native structure while being separated. This method is useful for studying protein-protein interactions and enzyme activities. Proteins migrate through the gel based on their size and charge, but their functional properties remain intact, making it ideal for analyzing native protein complexes.
=== Acquisitions === Grifols acquired its first group of plasma donation centers (43 in the U.S.) in 2002, taking over the company SeraCare, now known as Biomat. The following year, Grifols acquired Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California. In 2011, Grifols acquired the North American company Talecris Biotherapeutics, making Grifols the third-largest manufacturer of plasma-derived medicines in the world. Grifols acquired Novartis' blood transfusion diagnostics unit, based in Emeryville, California, in 2014. It was a part of Chiron, which had been acquired by Novartis in 2006. Grifols grew its transfusion medicine business with the acquisition of Hologic’s transfusion unit in 2017, leading the company’s creation of reagents and instrumentation based on NAT (nucleic acid testing) technology. In 2018, Grifols acquired the German company Haema and its network of donation centers and, in 2019, Grifols grew its network of donation centers with the addition of Interstate Blood Bank Inc. Today, the company has approximately 400 donation centers worldwide, most of them located in the U.S. Following a major equity investment in 2015, Grifols acquired the remaining shares of Alkahest in 2020 to help enhance the company’s discovery research and development to identify therapies based upon an understanding of the human plasma proteome. In 2021, the company acquired the remaining capital of GigaGen, a U.S.
Any substance, other than food, that is used to prevent, diagnose, treat or relieve symptoms of a disease or abnormal condition. Also refers to a substance that alters mood or body function, or that can be habit-forming or addictive, especially a narcotic. (NCI) Drug–drug interaction
Sources: en.wikipedia.org
=== Oxford debate walkout, 2013 === On 20 February 2013, Galloway walked out of a publicised debate when he found out that his opponent had Israeli citizenship. The debate, hosted by Oxford University's Christ Church, was on the topic "Israel should withdraw immediately from the West Bank". Galloway interrupted his opponent, Eylon Levy, a third-year PPE student, to ask whether he was an Israeli. When Levy acknowledged his joint British–Israeli nationality, Galloway stood up and stated "I don't recognise Israel and I don't debate with Israelis" and left the meeting. Explaining his actions on his Facebook page, Galloway wrote:
== History == The first documented case of gutter oil in Taiwan was reported in 1985. In a subsequent investigation, 22 people were arrested for involvement in a recycling oil ring over 10 years based in Taipei. The worst offender was sentenced to 7 years in prison. The first documented case of gutter oil in mainland China was reported in 2000, when a street vendor was found to be selling oil obtained from restaurant garbage disposals. Some street vendors and restaurants in China are reported to have illegally used recycled oil unfit for human consumption to cook food. In 2010, it was estimated that gutter oil represented 10% of China's edible oil market (with 1 in every 10 restaurants using it) and that 3 million tonnes of gutter oil were consumed in China annually, with a network of distributors of gutter oil across central and eastern China. In 2011, the Chinese government began a major crackdown on the re-use of gutter oil for human consumption. In 2011, they arrested 32 people for producing the oil and seized 90 tonnes of it in 14 provinces. This amount is equivalent to around one-tenth of the oil typically used by restaurants. Feng Ping of the China Meat Research Center has said that "[t]he illegal oil shows no difference in appearance and indicators after refining and purification, because the law breakers are skillful at coping with the established standards." In September 2012, an ongoing investigation into the suspected use of gutter oil as a raw material in the Chinese pharmaceutical industry was revealed.
The Refabricator experiment, which was delivered to the ISS aboard Cygnus NG-10 on November 19, 2018, processes plastic feedstock through multiple printing and recycling cycles to evaluate how many times the plastic materials can be re-used in the microgravity environment before their polymers degrade to unacceptable levels. Additionally, 3D printing in space can also account for the printing of meals. NASA's Advanced Food Technology program is currently investigating the possibility of printing food items in order to improve food quality, nutrient content, and variety. Airbus is developing and planning with the European Space Agency to send and test the first 3D-printer printing metals in space at the ISS in a year from 2022, and establishing space manufacturing in three to four years from 2022.
=== Third week (7–13 March) === On 7 March, Pakistani officials stated that they had carried out air strikes along the Pakistan-Afghanistan border, destroying several Afghan Taliban positions. The officials added the airstrikes inflicted heavy casualties on the Taliban forces, forcing them to abandon and flee from those positions. Meanwhile, Taliban officials said that Pakistani forces had bombed the provinces of Paktia, Paktika, Khost, Maidan Wardak, and Kunar, resulting in civilian casualties and damage to homes and shops. Taliban officials did not comment on the casualties suffered by their forces. Taliban officials also urged the United Nations Security Council (UNSC) to take action to stop Pakistan's attacks. They cited recent strikes on several Afghan provinces, civilian casualties, displacement, and the expulsion and harassment of Afghan refugees in Pakistan, and called on the UNSC to help end the situation. Taliban officials in Torkham border crossing area said that Pakistan's attacks have destroyed at least 150 shops, resulting heavy financial losses for Afghan business owners. In Nangarhar province, residents state that the Taliban had forced them to participate in a protest against Pakistan in Jalalabad, in some cases by offering cash payments. Three Policemen were killed and 31 people including five Policemen and 26 civilians were wounded in an IED attack targeting a police patrol in Wana. A drone attack on relatives of police peace committee killed two and wounded seven in Lakki Marwat District while a bomb blast killed two more civilians and wounded ten.
Sources: en.wikipedia.org
=== Multiplexed DIA (plexDIA) === The progress in data independent acquisition (DIA) enabled multiplexed quantitative proteomics with non-isobaric mass tags and a new method called plexDIA introduced in 2021. This new approach increases the number of data points by parallelizing both samples and peptides, thus achieving multiplicative gains. It has the potential to continue scaling proteomic throughput with new mass tags and algorithms. plexDIA is applicable to both bulk and single-cell samples and is particularly powerful for single-cell proteomics.
On 2 May, the Jordanian Air Force led an operation called "Operation Jordanian Deterrence", in the cities of Shahba, Al-Kafr, Arman and Al-Anat, controlled by the Druze militias, to counter border drug trafficking, in the city of Shahba, the Jordanian Air Force bombed the former State Security branch. On the same day the Syrian government also operated against drug trafficker. On 3 May, the National Guard published a statement where they condemned the Jordan's operation. The reason for the condemnation was the lack of coordination between Jordanian government and the National Guard.. On the same day a rebel armed group attacked Syrians positions, the attacks were similar to those of the National Guard. On 4 May, the National Guard targeted security posts in Rimat Hazem and Walgha. On 5 May, the National Guard's 501st Battalion (Hamza Knights) clashed with the Syrian Armed Forces. On 6 May, retired Jordanian military analyst, Major General Abu Nowar, told Al Jazeera English that the airstrikes were a deterrent to drug cartels, as well as a warning to external actors—such as Israel and Israel-allied elements in Suwayda—seeking to capitalize on the power struggle. On 9 May, two inner faction of the National Guard, the Saraya al-Jabal faction and the Jala Abu Daqqa faction, clashed with each other, the clashes began when Saraya al-Jabal arrested members of the Jala Abu Daqqa faction after they were accused of vehicle theft.
The samples were originally taken to test for preventable diseases, but with the advance in genomic sequencing technologies many samples are being kept for DNA identification and research, increasing the possibility that more children will be opted out of newborn screening from parents who see the kept samples as a form of research done on their child.
== Medical uses == Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria. Some medical uses are:
== Career == The research Horsley explored throughout the duration of her doctorate degree, which was supervised by Grace Pavlath, focused on the transcription factors involved in the development of skeletal muscle tissue. The lab that Horsley worked in discovered that smaller muscles in mice were associated with a lack of transcription factor NFATc2. She was able to determine that factor NFATc2 was a foundational component that allotted myoblast cells to fuse and develop muscle fibers. She also found that NFATc2 factor regulates the transcription of a cytokine, IL-4. Horsley later decided to shift away from muscle research to complete her postdoctoral training under the guidance of Elaine Fuchs at Rockefeller University. It was during this process that she investigated the factors that influence stem cell development in the skin, specifically the transcription of factor Blimp-1. After finding that eliminating the gene that encoded Blimp-1 led to oily skin in mice, Horsley discovered that Blimp-1 monitors the size of the sebaceous gland. In 2009, Horsley joined the faculty of Yale University and was promoted to an associate professor of dermatology in 2011, as well as the Maxine F. Singer '57 Assistant Professor of Molecular, Cellular and Developmental Biology.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.